Mechanism of HPD-Mediated Glycolytic Reprogramming in Ovarian Cancer

Authors

  • Siyu Xu School of Pharmacy, Nankai University, Tianjin, China

DOI:

https://doi.org/10.54097/5w7y7r24

Keywords:

HPD, RNA-Binding Protein, Glycolysis, Ovarian Cancer

Abstract

Ovarian cancer is hard to diagnose at an early stage and has a high rate of recurrence. Because of this, its clinical treatment faces serious challenges. In recent years, studies have found that metabolic reprogramming, especially the abnormal activation of glycolysis, plays a key role in the progression of ovarian cancer. 4-Hydroxyphenylpyruvate dioxygenase (HPD) is an important molecule with two functions. It acts both as a metabolic enzyme and as an RNA-binding protein. Recent studies have confirmed that HPD is abnormally expressed in many tumors and is involved in the regulation of malignant behavior. This paper systematically reviews the molecular mechanism of HPD as an RNA-binding protein. HPD recognizes the RRACH motif on target mRNAs and promotes the translation of the key glycolytic enzymes TPI and ENO1. As a result, it increases glycolytic flux and cell proliferation in ovarian cancer cells. This paper also summarizes the potential therapeutic value of the small-molecule HPD inhibitor NTBC and its combined use with paclitaxel. These findings provide a new theoretical basis and new strategic directions for the precise treatment of ovarian cancer.

Downloads

Download data is not yet available.

References

Rooth, C. (2013). Ovarian cancer: Risk factors, treatment and management. British Journal of Nursing, 22(17), S23–S30. https://doi.org/10.12968/bjon.2013.22.17.S23.

[2] Kurman, R. J., & Shih, I. M. (2016). The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. The American Journal of Pathology, 186(4), 733–747. https://doi.org/10.1016/j. ajpath. 2015.12.011.

[3] Lheureux, S., Braunstein, M., & Oza, A. M. (2019). Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA: A Cancer Journal for Clinicians, 69(4), 280–304. https://doi.org/10.3322/caac.21562.

[4] Li, X. J., et al. (2024). Ovarian cancer: Diagnosis and treatment strategies (Review). Oncology Letters, 28(3). https://doi.org/10.3892/ol.2024.13567.

[5] Balkin, M., & Altchek, A. (Patent). Early detection of cancer esp. ovarian carcinoma—in humans prior to full presentation of the disease. U.S. Patent Application.

[6] Webb, P. M., & Jordan, S. J. (2017). Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 3–14. https://doi.org/10.1016/j. bpobgyn. 2016. 10.003.

[7] Wu, M., et al. (2024). Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer. International Journal of Biological Sciences, 20(2), 486–501. https://doi.org/10.7150/ijbs.89575.

[8] Yang, C., et al. (2020). Immunotherapy for ovarian cancer: Adjuvant, combination, and neoadjuvant. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01577.

[9] Yuan, Y. Y., et al. (2022). Cancer metabolism and tumor microenvironment: Fostering each other? Science China Life Sciences, 65(2), 236–279. https://doi.org/10.1007/s11427-021-1994-2.

[10] Heiden, M. G. V., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. https://doi.org/10. 1126/ science.1160969.

[11] Zhang, X. Y., et al. (2018). Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. The International Journal of Biochemistry & Cell Biology, 95, 9–16. https://doi.org/10.1016/j.biocel.2017.12.005.

[12] Lim, J. S., et al. (2022). Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth. Cell Death & Disease, 13(11), 944. https://doi.org/ 10. 1038/s41419-022-05395-6.

[13] Mazurek, S., et al. (2005). Pyruvate kinase type M2 and its role in tumor growth and spreading. Seminars in Cancer Biology, 15(4), 300–308. https://doi.org/10.1016/j.semcancer.2005.04.005.

[14] Wang, S. J., et al. (2022). RNA-binding proteins and cancer metastasis. Seminars in Cancer Biology, 86, 748–768. https://doi.org/10.1016/j.semcancer.2022.09.008.

[15] Li, W., Deng, X. L., & Chen, J. J. (2022). RNA-binding proteins in regulating mRNA stability and translation: Roles and mechanisms in cancer. Seminars in Cancer Biology, 86, 664–677. https:// doi. org/10.1016/j.semcancer.2022.09.007.

[16] Moran, G. R. (2005). 4-Hydroxyphenylpyruvate dioxygenase. Archives of Biochemistry and Biophysics, 433(1), 117–128. https://doi.org/10.1016/j.abb.2004.09.027.

[17] Shan, C. L., et al. (2019). 4-hydroxyphenylpyruvate dioxygenase promotes lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-AMPK/HDAC10/G6PD axis. Cell Death & Disease, 10(6), 4245. https://doi.org/10.1038/s41419-019-1654-8.

[18] Tong, M., et al. (2021). Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. Cell Reports, 36(8), 109621. https://doi.org/10.1016/j. celrep. 2021.109621.

[19] Wang, X. Y., et al. (2019). HPD overexpression predicts poor prognosis in breast cancer. Pathology Research and Practice, 215(9), 152516. https://doi.org/10.1016/j.prp.2019.152516.

[20] Xie, F., et al. (2025). HPD is an RNA-binding protein sustaining ovarian cancer cell glycolysis, tumor growth, and drug resistance. Advanced Science, 12(17), e2412876. https://doi.org/10. 1002/ advs. 202412876.

[21] Castello, A., et al. (2012). Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell, 149(6), 1393–1406. https://doi.org/10.1016/j.cell.2012.04.031.

[22] Ghosh, S. G., et al. (2021). Biallelic variants in HPDL, encoding 4-hydroxyphenylpyruvate dioxygenase-like protein, lead to an infantile neurodegenerative condition. Genetics in Medicine, 23(3), 524–533. https://doi.org/10.1038/s41436-020-01036-7.

[23] Tao, Y. N., et al. (2024). Alternative splicing and related RNA binding proteins in human health and disease. Signal Transduction and Targeted Therapy, 9(1), 33. https://doi.org/10.1038/s41392-024-01769-9.

[24] Lunde, B. M., Moore, C., & Varani, G. (2007). RNA-binding proteins: Modular design for efficient function. Nature Reviews Molecular Cell Biology, 8(6), 479–490. https://doi.org/10.1038/ nrm2178.

[25] Pereira, B., Billaud, M., & Almeida, R. (2017). RNA-binding proteins in cancer: Old players and new actors. Trends in Cancer, 3(7), 506–528. https://doi.org/10.1016/j.trecan.2017.05.003.

[26] Schwanhäusser, B., et al. (2011). Global quantification of mammalian gene expression control. Nature, 473(7347), 337–342. https://doi.org/10.1038/nature10098.

[27] Xie, Y. J., et al. (2019). HPD degradation regulated by the TTC36-STK33-PELI1 signaling axis induces tyrosinemia and neurological damage. Nature Communications, 10(1), 4263. https:// doi. org /10.1038/s41467-019-12245-4.

[28] Akram, M. (2013). Mini-review on glycolysis and cancer. Journal of Cancer Education, 28(3), 454–457. https://doi.org/10.1007/s13187-013-0486-9.

[29] Sherman, B. T., et al. (2022). DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Research, 50(W1), W216–W221. https://doi.org/10.1093/nar/gkac394.

[30] Miao, D. Y., et al. (2025). Photothermal nanofiber-mediated photoporation for gentle and efficient intracellular delivery of macromolecules. Nature Protocols, 20(7), 2142–2171. https://doi.org/ 10.1038/ s41596-025-01041-1.

[31] Yamashita, S., et al. (2011). Structures of the first and second double-stranded RNA-binding domains of human TAR RNA-binding protein. Protein Science, 20(1), 118–130. https://doi.org/10. 1002/ pro.534.

[32] Zhang, X. L., et al. (2021). Blocking the IGF2BP1-promoted glucose metabolism of colon cancer cells via direct de-stabilizing mRNA of the LDHA enhances anticancer effects. Molecular Therapy—Nucleic Acids, 23, 835–846. https://doi.org/10.1016/j.omtn.2021.01.025.

[33] Tan, V. P., & Miyamoto, S. (2015). HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection. Autophagy, 11(6), 963–964. https://doi.org/10.1080/ 15548627. 2015. 1041971.

[34] Wu, L., et al. (2019). Upregulation of SCNN1A promotes cell proliferation, migration, and predicts poor prognosis in ovarian cancer through regulating epithelial–mesenchymal transformation. Cancer Biotherapy and Radiopharmaceuticals, 34(10), 642–649. https://doi.org/10. 1089/cbr. 2019. 2789.

[35] Patra, K. C., & Hay, N. (2014). The pentose phosphate pathway and cancer. Trends in Biochemical Sciences, 39(8), 347–354. https://doi.org/10.1016/j.tibs.2014.06.005.

[36] Lu, H. S., Forbes, R. A., & Verma, A. (2002). Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. Journal of Biological Chemistry, 277(26), 23111–23115. https://doi.org/10.1074/jbc.M202496200.

[37] Mukherjee, J., et al. (2016). PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. International Journal of Cancer, 139(1), 99–111. https: // doi.org/10.1002/ijc.30047.

[38] Brandi, J., et al. (2016). The antioxidant uncoupling protein 2 stimulates hnRNPA2/B1, GLUT1 and PKM2 expression and sensitizes pancreas cancer cells to glycolysis inhibition. Free Radical Biology and Medicine, 101, 305–316. https://doi.org/10.1016/j. freeradbiomed. 2016.10.012.

[39] Chen, M., Zhang, J., & Manley, J. L. (2010). Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Research, 70(22), 8977–8980. https://doi.org/10.1158/0008-5472.CAN-10-1863.

[40] Xu, J. F., et al. (2024). Development of miRNA-based PROTACs targeting Lin28 for breast cancer therapy. Science Advances, 10(38), eadp0752. https://doi.org/10.1126/sciadv.adp0752.

[41] Li, F. F., et al. (2022). MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS. Cell Death & Disease, 13(6), 533. https://doi.org/10.1038/s41419-022-04982-x.

[42] Liu, T., et al. (2021). The RNA binding protein QKI5 suppresses ovarian cancer via downregulating transcriptional coactivator TAZ. Molecular Therapy—Nucleic Acids, 26, 388–400. https://doi.org/ 10. 1016/ j.omtn.2021.07.015.

[43] Xu, T., et al. (2024). Tropomyosin1 isoforms underlie epithelial to mesenchymal plasticity, metastatic dissemination, and resistance to chemotherapy in high-grade serous ovarian cancer. Cell Death & Differentiation, 31(4), 511–523. https://doi.org/10.1038/s41422-024-01432-6.

[44] Dong, J., et al. (2023). Structure-based discovery of pyrazole-benzothiadiazole as human HPPD inhibitors. Structure, 31(12), 1216–1227.e4. https://doi.org/10.1016/j.str.2023.10.005.

Downloads

Published

10-07-2026

Issue

Section

Articles

How to Cite

Xu, S. (2026). Mechanism of HPD-Mediated Glycolytic Reprogramming in Ovarian Cancer. International Journal of Biology and Life Sciences, 15(2), 62-69. https://doi.org/10.54097/5w7y7r24